Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-10 22:45:30 UTC |
---|
Update Date | 2022-09-22 17:45:00 UTC |
---|
HMDB ID | HMDB0245703 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate |
---|
Description | Molsidomine, also known as molsidomin stada or corvaton, belongs to the class of organic compounds known as morpholines. These are organic compounds containing a morpholine moiety, which consists of a six-member aliphatic saturated ring with the formula C4H9NO, where the oxygen and nitrogen atoms lie at positions 1 and 4, respectively. Molsidomine is a prodrug that is hydrolysed to linsidomine (SIN-1) in the liver via first-pass effect, which subsequently releases NO. 44–59% of molsidomine reach the bloodstream in unchanged form, 3–11% of which are bound to plasma proteins. Molsidomine is an extremely weak basic (essentially neutral) compound (based on its pKa). Ergolines can antagonise the effects of molsidomine. It is also used to treat angina in the context of an acute myocardial infarction. The substance is sensitive to ultraviolet light at wavelengths shorter than 320 nm. This compound has been identified in human blood as reported by (PMID: 31557052 ). 1-ethoxy-n-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1 InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3 |
---|
Synonyms | Value | Source |
---|
Corvaton | MeSH | Molsidain | MeSH | Morsydomine | MeSH | SIN 10 | MeSH | Molsidomin stada | MeSH | Von CT, molsidomin | MeSH | Molsi 1a pharma | MeSH | Molsibeta | MeSH | SIN10 | MeSH | Molsi-azu | MeSH | Molsicor | MeSH | Fali cor | MeSH | Molsihexal | MeSH | Molsi azu | MeSH | Molsidomin | MeSH | Molsidomin ratiopharm | MeSH | Fali-cor | MeSH | SIN-10 | MeSH | Korvatone | MeSH | Molsidomin heumann | MeSH | Molsidomin-ratiopharm | MeSH | Molsi puren | MeSH | Sydnopharm | MeSH | Duracoron | MeSH | MTW-Molsidomin | MeSH | Heumann, molsidomin | MeSH | Molsiket | MeSH | MTW Molsidomin | MeSH | Molsidomin von CT | MeSH | Corpea | MeSH | Molsi-puren | MeSH | Alpharma brand OF molsidomine | MeSH | Molsidomine normon brand | MeSH | Molsidominratiopharm | MeSH | Stadapharm brand OF molsidomine | MeSH | CT Arzneimittel brand OF molsidomine | MeSH | 1a Brand OF molsidomine | MeSH | Azupharma brand OF molsidomine | MeSH | Molsidomine ratiopharm brand | MeSH | Normon brand OF molsidomine | MeSH | Schwarz brand OF molsidomine | MeSH | Molsidomine | MeSH | Molsidomine aventis brand | MeSH | Molsidomine salutas brand | MeSH | Molsidomine schwarz brand | MeSH | Molsidomine CT-arzneimittel brand | MeSH | Sanol brand OF molsidomine | MeSH | CT-Arzneimittel brand OF molsidomine | MeSH | Hexal brand OF molsidomine | MeSH | Merck dura brand OF molsidomine | MeSH | Molsidomine heumann brand | MeSH | Molsidomine stadapharm brand | MeSH | Salutas brand OF molsidomine | MeSH | Heumann brand OF molsidomine | MeSH | Molsidomine betapharm brand | MeSH | Aventis brand OF molsidomine | MeSH | Molsidomine azupharma brand | MeSH | Molsidomine hexal brand | MeSH | Molsidomine MTW brand | MeSH | Betapharm brand OF molsidomine | MeSH | Ratiopharm brand OF molsidomine | MeSH | MTW Brand OF molsidomine | MeSH | Molsidomine 1a brand | MeSH | Molsidomine alpharma brand | MeSH | Molsidomine sanol brand | MeSH | Ethyl N-[3-(morpholin-4-yl)-5H-1,2,3λ⁵-oxadiazol-5-ylidene]carbamic acid | Generator |
|
---|
Chemical Formula | C9H14N4O4 |
---|
Average Molecular Weight | 242.235 |
---|
Monoisotopic Molecular Weight | 242.101504947 |
---|
IUPAC Name | 5-[(ethoxycarbonyl)azanidyl]-3-(morpholin-4-yl)-1,2,3λ⁵-oxadiazol-3-ylium |
---|
Traditional Name | 5-[(ethoxycarbonyl)azanidyl]-3-(morpholin-4-yl)-1,2,3λ⁵-oxadiazol-3-ylium |
---|
CAS Registry Number | Not Available |
---|
SMILES | CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1 |
---|
InChI Identifier | InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3 |
---|
InChI Key | XLFWDASMENKTKL-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as morpholines. These are organic compounds containing a morpholine moiety, which consists of a six-member aliphatic saturated ring with the formula C4H9NO, where the oxygen and nitrogen atoms lie at positions 1 and 4, respectively. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Oxazinanes |
---|
Sub Class | Morpholines |
---|
Direct Parent | Morpholines |
---|
Alternative Parents | |
---|
Substituents | - Morpholine
- Carbonic acid derivative
- Dialkyl ether
- Ether
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Azacycle
- Oxacycle
- Organooxygen compound
- Organonitrogen compound
- Carbonyl group
- Organic nitrogen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Aliphatic heteromonocyclic compound
|
---|
Molecular Framework | Aliphatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate GC-MS (Non-derivatized) - 70eV, Positive | splash10-01dj-7910000000-63f8ea7ee27b88f0912f | 2021-09-23 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 10V, Positive-QTOF | splash10-0006-6490000000-c5e4bc21cb85b4e60a70 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 20V, Positive-QTOF | splash10-000j-9220000000-abafa3380cf8a5a4d0bd | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 40V, Positive-QTOF | splash10-000l-9400000000-daea7c7e4e6043483506 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 10V, Negative-QTOF | splash10-0006-5290000000-6d4f7dd885c9fb6c59ad | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 20V, Negative-QTOF | splash10-002n-9560000000-93fecea706c4877048ad | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 40V, Negative-QTOF | splash10-052v-9000000000-a53b47a7b42292d341b5 | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum |
|
---|